Close Menu

by Jim Reddoch

The stock market has had a rough year, but the performance of the Nasdaq — down 15 percent — is downright enviable for biotech investors. The BTK stock average is down 28 percent for 2002 to date. Genomics stocks have largely tracked the BTK in ’02, but underperformed in 2001.

This column takes on the idea of “trough valuations,” or in other words, how low can they go?

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An Associated Press report says China refrained from releasing the SARS-CoV-2 genome for more than a week in January, frustrating the World Health Organization.

The Lancet and the New England Journal of Medicine have issued expressions of concern regarding the data used in two COVID-19 papers, the New York Times reports. 

Researchers have sequenced the genome of the mayfly, garnering insight into how insects evolved wings, Science reports.

In Genome Research this week: gene expression in primate brain regions, inversions and breakpoint inverted repeats in the human genome, and more.